Amgen Responds To Reports About Use And Safety Of EPOGEN And Aranesp In CKD Anemia Therapy
Mon, 11 Dec 2006 08:00 AM EST
... Amgen (NASDAQ:AMGN), today posted to its corporate web site documents intended to clarify Amgen's position on the use of EPOGEN(R) (Epoetin alfa) and Aranesp(R) (darbepoetin alfa) and to correct what the company believes are misleading and inaccurate news reports regarding the use of its drugs. [click link for full article] ...
Related Topics
- Darbepoetin alfa
- Food Safety
- Anemia
- Sickle Cell Anemia
- Drug Safety
- Aplastic Anemia
- Fire Safety
- Child Safety
- Sports Safety
- Epoetin Alfa Injection
- Electrical Safety
- Workplace Safety & Health
- Safety (General)
- Traffic Safety
- Vaccine Safety and Adverse Event Reports
- Safety
- Pernicious Anemia
- Machine Safety
- Iron Deficiency Anemia
- Chemical Safety

Not Signed In -


